» Articles » PMID: 21440910

Characteristics of Myasthenia Gravis According to Onset-age: Japanese Nationwide Survey

Overview
Journal J Neurol Sci
Publisher Elsevier
Specialty Neurology
Date 2011 Mar 29
PMID 21440910
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To clarify the prevalence and clinical characteristics of myasthenia gravis (MG) in Japan.

Methods: We performed a nationwide epidemiological survey of MG in Japan. The clinical features were compared among five groups of patients, divided according to onset age. A generalized additive model (GAM) was used to assess the linearity of these relationships.

Results: A total of 8542 patients were reported, and detailed data were analyzed for 3141 patients. The estimated number of MG patients in Japan was 15,100, giving a prevalence of 11.8 per 100,000. Elderly-onset MG (≥ 65 years) accounted for 7.3% in 1987 (adjusted for population in 2005), but this had increased to 16.8% in 2006. Infantile-onset MG (0-4 years) accounted for 10.1% in 1987, and was still as high as 7.0% in 2006. The rate of ocular MG was highest (80.6%) in infantile-onset and lowest (26.4%) in early-onset disease, but the rate rose again in the late-onset group. GAM analysis of the ocular form showed a U-shaped curve, with a dip in the 20s. Anti-acetylcholine receptor antibodies were positive in only 50% of infantile-onset, but nearly 90% of elderly-onset patients. GAM analyses assessing the concurrence of thymoma and hyperplasia both showed reversed U-shapes, with peaks in the 50s and 20s-40s, respectively.

Conclusions: Persistent high incidence of infantile-onset disease and clinical heterogeneity according to onset age are characteristic features of MG in Japan.

Citing Articles

Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients.

Xie N, Liu Q, Wen Q, Wang Y, Liu H, Jiang Y Ther Adv Neurol Disord. 2025; 18():17562864241309793.

PMID: 39803329 PMC: 11713957. DOI: 10.1177/17562864241309793.


Differentiation and characterization of non-thymomatous ocular myasthenia gravis children with CT.

Cai Y, Cheng Z, Yang Y, Xu B, Feng Q, Liu X Acta Neurol Belg. 2024; 125(1):149-156.

PMID: 39476226 DOI: 10.1007/s13760-024-02669-9.


Correlation Between the Prevalence of Myasthenia Gravis and the Frequency of Class II Human Leucocyte Antigen Alleles in Various Geographical Locations Around the World.

Kurian M, Khera N Cureus. 2024; 16(9):e69791.

PMID: 39308848 PMC: 11416033. DOI: 10.7759/cureus.69791.


Assessing the lack of diversity in genetics research across neurodegenerative diseases: A systematic review of the GWAS Catalog and literature.

Jonson C, Levine K, Lake J, Hertslet L, Jones L, Patel D Alzheimers Dement. 2024; 20(8):5740-5756.

PMID: 39030740 PMC: 11350004. DOI: 10.1002/alz.13873.


Immune mediated myasthenia gravis in children, current concepts and new treatments: A narrative review article.

Tavasoli A Iran J Child Neurol. 2024; 18(3):21-42.

PMID: 38988843 PMC: 11231678. DOI: 10.22037/ijcn.v18i3.45054.